文献速递细菌感染、耐药与抗菌药物医院感染防控

抗生素与非抗生素药物与艰难梭菌感染风险的药典范围病例队列研究

Antibiotic and Nonantibiotic Drugs Associated With Clostridioides difficile Infection Risk: a Pharmacopoeia-Wide Case-Cohort Study.
PubMed 文献 · J Infect Dis · 2026-01-01

该病例队列研究纳入2018至2023年间16 196例首次社区发病艰难梭菌感染(CDI)病例与549 831名对照,分析335种门诊口服药物的CDI风险关联。调整混杂后,阿莫西林-克拉维酸、克林霉素、环丙沙星、头孢氨苄贡献最大;非抗生素药物中泮托拉唑与富马酸亚铁亦升高风险,二甲双胍呈保护性关联。

要点

  • 克林霉素与CDI风险关联最强(OR 16.83),阿莫西林-克拉维酸次之(OR 6.05)。
  • 泮托拉唑(OR 1.33)与富马酸亚铁(OR 1.71)为非抗生素药物中风险升高最显著者。
  • 二甲双胍与CDI风险降低相关(OR 0.67),提示潜在药物再利用方向。

核心结论

  • 门诊口服抗生素仍是社区老年人群CDI的主要风险因素,部分非抗生素药物亦与风险升高相关,二甲双胍呈保护性关联,体外抗共生菌活性与CDI风险正相关。

研究设计与样本

  • 病例队列研究,纳入2018至2023年间年龄>65岁、既往30天未住院的居民,共16 196例首次 incident CDI病例与549 831名对照,分析335种门诊口服药物,采用logistic回归并调整年龄、性别、年份季度、地区、合并症、医疗暴露及药物暴露。

主要发现

  • 调整后CDI风险关联最强的抗生素为克林霉素(OR 16.83,95%CI 15.53-18.24)、阿莫西林-克拉维酸(OR 6.05,95%CI 5.69-6.43)、环丙沙星(OR 3.83,95%CI 3.59-4.09)和头孢氨苄(OR 3.05,95%CI 2.86-3.25)。
  • 非抗生素药物中泮托拉唑(OR 1.33,95%CI 1.27-1.39)与富马酸亚铁(OR 1.71,95%CI 1.61-1.82)风险升高。
  • 对182种药物子集的meta回归显示,体外抗共生菌活性与CDI风险正相关(P<.001)。

临床怎么用

  • 社区老年患者处方抗生素时应评估CDI风险,克林霉素等高风险药物需谨慎使用。
  • 对使用泮托拉唑或铁剂的患者应关注CDI相关症状,避免不必要用药。
  • 二甲双胍的保护性关联提示其可能作为药物再利用候选,但需进一步验证。

局限性

  • 研究为观察性设计,残余混杂可能影响关联估计。
  • 仅评估门诊口服药物暴露,未涵盖住院或非口服用药。
  • 研究对象限于年龄>65岁且30天内未住院者,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clostridioides difficile infection (CDI) is principally precipitated by antibiotics, due to their disruption of gut commensal bacteria. The comparative role of nonantibiotic drugs is poorly characterized. METHODS: We examined the contribution of antibiotic and nonantibiotic drugs to CDI risk among residents age >65 years old and not hospitalized in the prior 30 days, between 2018 and 2023. The study used a case-cohort study design, with logistic regression analysis. The case definition consisted of first incident CDI, identified using comprehensive C. difficile testing, hospitalization, and treatment data. Outpatient oral drug exposures were measured in a 1-90-day window prior to case and control days. Adjusted regression models included covariates for age, sex, year and quarter, region, comorbid conditions, healthcare exposures, and drug exposures. RESULTS: Among 16 196 CDI case patients and 549 831 controls, 335 drugs were included. After adjustment, the antibiotics amoxicillin-clavulanate (odds ratio [OR], 6.05 [95% confidence interval (CI), 5.69-6.43]), clindamycin (16.83 [15.53-18.24]), ciprofloxacin (3.83 [3.59-4.09]), and cephalexin (3.05 [2.86-3.25]), were the largest contributors to CDI risk. Nonantibiotic drugs pantoprazole (OR, 1.33 [95% CI, 1.27-1.39]) and ferrous fumarate (1.71 [1.61-1.82]) were the next largest. Metformin had a protective association (OR, 0.67 [95% CI, .63-.72]). In a meta-regression on a subset of 182 drugs, in vitro anticommensal activity was positively associated with CDI risk (P < .001). CONCLUSIONS: This study provides insights into CDI etiology and avenues for stewardship and drug repurposing to combat CDI and antimicrobial resistance.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Brown KA, Coburn B, Hernandez A, et al. Antibiotic and Nonantibiotic Drugs Associated With Clostridioides difficile Infection Risk: a Pharmacopoeia-Wide Case-Cohort Study. J Infect Dis. 2026. PMID: 41830216. doi:10.1093/infdis/jiag001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。